Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | microtubule-associated protein tau | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Schistosoma japonicum | ko:K04380 microtubule-associated protein tau, putative | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Echinococcus granulosus | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Echinococcus multilocularis | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.2792 | 0.9118 | 1 |
Schistosoma mansoni | thyroid hormone receptor | 0.3038 | 1 | 1 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0246 | 0 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.2103 | 0.2103 |
Schistosoma mansoni | hypothetical protein | 0.2792 | 0.9118 | 0.9118 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0246 | 0 | 0.5 |
Onchocerca volvulus | 0.0246 | 0 | 0.5 | |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.2792 | 0.9118 | 0.9118 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0246 | 0 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.3038 | 1 | 1 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0278 | 0.0113 | 0.5 |
Brugia malayi | Nuclear hormone receptor-like 1 | 0.0765 | 0.1857 | 1 |
Loa Loa (eye worm) | nuclear hormone receptor-like 1 | 0.0649 | 0.1441 | 1 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.2103 | 0.2306 |
Brugia malayi | Nuclear hormone receptor-like 1 | 0.0649 | 0.1441 | 0.7761 |
Brugia malayi | Nuclear hormone receptor-like 1 | 0.0649 | 0.1441 | 0.7761 |
Loa Loa (eye worm) | hypothetical protein | 0.0635 | 0.1392 | 0.9654 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.2103 | 0.2103 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (binding) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.